Sinovac Biotech, a biopharma company in China, has announced that its wholly-owned subsidiary company in Hong Kong has received the Certificate of Drug/Product Registration from the Hong Kong Department of Health for its seasonal influenza vaccine Anflu. The company filed the application with the Hong Kong Department of Health for the drug registration certificate for Anflu in November 2009. Obtaining the drug certificate in Hong Kong is a continuation of Sinovac's strategy to pursue opportunities to export its vaccines manufactured in mainland China to targeted areas and countries around the globe. Dr Weidong Yin, chairman, president & CEO of Sinovac, stated, "We are advancing our international sales strategy by obtaining regulatory approvals in targeted areas and countries that will enable us generate sales by exporting our commercialized vaccines. We have successfully registered Anflu in Hong Kong and are actively evaluating marketing and distribution opportunities in this market." Sinovac Biotech has also been selected by the Beijing Centers for Disease Control and Prevention (Beijing CDC) as one of the five manufacturers to supply seasonal influenza vaccine to the citizens of Beijing. As part of the bidding process, the Beijing CDC evaluated potential suppliers and assigned scores for different factors, including product quality, service and price. Based on the comprehensive score, Sinovac was selected as the first priority supplier. Based on the first contract with the Beijing CDC, Sinovac will supply 375,000 doses of Anflu, valued at $1.3 million. The total quantity to be supplied will depend on the actual demand in Beijing. In order to prevent and control the seasonal flu, the Beijing CDC plans to provide free inoculations against the seasonal influenza to Beijing citizens, inclusive of elderly people (over the age of 60) and elementary and secondary school age children. And Beijing CDC plans to order total 2.8 million doses for this vaccination campaign.